Repository logoRepository logo
GRO
  • GRO.data
  • GRO.plan
Help
  • English
  • Deutsch
Log In
New user? Click here to register.Have you forgotten your password?
Publications
Researcher
Organizations
Other
  • Journals
  • Series
  • Events
  • Projects
  • Working Groups

Browsing by Author "Barman, P."

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Results Per Page
  • Sort Options
  • Some of the metrics are blocked by your 
    consent settings
    The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response
    (Nature Publishing Group, 2015)
    Biernacka, J. M.
    ;
    Sangkuhl, K.
    ;
    Jenkins, Gareth B.
    ;
    Whaley, R. M.
    ;
    Barman, P.
    ;
    Batzler, A.
    ;
    Altman, Russ B.
    ;
    Arolt, V.
    ;
    Brockmoeller, Juergen  
    ;
    Chen, C. H.
    ;
    Domschke, Katharina
    ;
    Hall-Flavin, D. K.
    ;
    Hong, C. J.
    ;
    Illi, A.
    ;
    Ji, Y.
    ;
    Kampman, O.
    ;
    Kinoshita, T.
    ;
    Leinonen, E.
    ;
    Liou, Y. J.
    ;
    Mushiroda, T.
    ;
    Nonen, S.
    ;
    Skime, M. K.
    ;
    Wang, L.
    ;
    Baune, B. T.
    ;
    Kato, M.
    ;
    Liu, Y. L.
    ;
    Praphanphoj, V.
    ;
    Stingl, Julia Carolin
    ;
    Tsai, S. J.
    ;
    Kubo, M.
    ;
    Klein, Teri E.
    ;
    Weinshilboum, R.
    Response to treatment with selective serotonin reuptake inhibitors (SSRIs) varies considerably between patients. The International SSRI Pharmacogenomics Consortium (ISPC) was formed with the primary goal of identifying genetic variation that may contribute to response to SSRI treatment of major depressive disorder. A genome-wide association study of 4-week treatment outcomes, measured using the 17-item Hamilton Rating Scale for Depression (HRSD-17), was performed using data from 865 subjects from seven sites. The primary outcomes were percent change in HRSD-17 score and response, defined as at least 50% reduction in HRSD-17. Data from two prior studies, the Pharmacogenomics Research Network Antidepressant Medication Pharmacogenomics Study (PGRN-AMPS) and the Sequenced Treatment Alternatives to Relieve Depression (STAR D) study, were used for replication, and a meta-analysis of the three studies was performed (N = 2394). Although many top association signals in the ISPC analysis map to interesting candidate genes, none were significant at the genome-wide level and the associations were not replicated using PGRN-AMPS and STAR D data. Top association results in the meta-analysis of response included single-nucleotide polymorphisms (SNPs) in the HPRTP4 (hypoxanthine phosphoribosyltransferase pseudogene 4)/VSTM5 (V-set and transmembrane domain containing 5) region, which approached genome-wide significance (P = 5.03E - 08) and SNPs 5' upstream of the neuregulin-1 gene, NRG1 (P = 1.20E - 06). NRG1 is involved in many aspects of brain development, including neuronal maturation and variations in this gene have been shown to be associated with increased risk for mental disorders, particularly schizophrenia. Replication and functional studies of these findings are warranted.

About

About Us
FAQ
ORCID
End User Agreement
Privacy policy
Cookie consent
Imprint

Contact

Team GRO.publications
support-gro.publications@uni-goettingen.de
Matrix Chat: #support_gro_publications
Feedback

Göttingen Research Online

Göttingen Research Online bundles various services for Göttingen researchers:

GRO.data (research data repository)
GRO.plan (data management planning)
GRO.publications (publication data repository)
Logo Uni Göttingen
Logo Campus Göttingen
Logo SUB Göttingen
Logo eResearch Alliance

Except where otherwise noted, content on this site is licensed under a Creative Commons Attribution 4.0 International license.